1-12 of 12
Omar Alexis Castaneda Puglianini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Charlotte B Wagner, Karen Sweiss, Eric Anto, Rebecca Gonzalez, Omar Alexis Castaneda Puglianini, Ciara Louise L. Freeman, Filip Ionescu, Krina K. Patel, Christopher Ferreri, Mahmoud Gaballa, Leyla Shune, Joseph P McGuirk, Surbhi Sidana, Vanna Hovanky, Jack Khouri, Danai Dima, Hamza Hashmi, James A Davis, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Jr., Peter A. Forsberg, Megan Herr, Doris K. Hansen, Douglas Sborov, Mehmet H. Kocoglu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4880.
https://doi.org/10.1182/blood-2023-187440
Published: 2023
Journal Articles

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Alexis Castaneda Puglianini, Ciara L. Freeman, Gabriel De Avila, Surbhi Sidana, Leyla O. Shune, Douglas W. Sborov, James Davis, Charlotte B. Wagner, M. Hakan Kocoglu, Shebli Atrash, Peter M. Voorhees, Gary Simmons, Christopher J. Ferreri, Nilesh Kalariya, Aishwarya Sannareddy, Danai Dima, Jack Khouri, Joseph P. McGuirk, Frederick L. Locke, Rachid C. Baz, Krina Patel, Melissa Alsina
Journal: Blood
Blood (2022) 140 (Supplement 1): 4642–4645.
https://doi.org/10.1182/blood-2022-164828
Published: 2022
Journal Articles

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Omar Alexis Castaneda Puglianini, Lauren C. Peres, Doris K. Hansen, Taiga Nishihori, Ariel F Grajales-Cruz, Brandon J. Blue, Jason Brayer, Ciara L. Freeman, Kenneth H. Shain, Hien D. Liu, Jose Ochoa, Frederick L. Locke, Rachid C. Baz, Melissa Alsina
Journal: Blood
Blood (2022) 140 (Supplement 1): 7538–7539.
https://doi.org/10.1182/blood-2022-170135
Published: 2022
Journal Articles

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Doris K. Hansen, Lauren C. Peres, Ciara L. Freeman, Omar Alexis Castaneda Puglianini, Rawan Faramand, Laura B. Oswald, Kayla M. Reid, Gabriel De Avila, Brandon J. Blue, Ariel F. Grajales-Cruz, Jose Ochoa, Alexandria Shrewsbury, Cole T. Powell, Christina Copponex, Krista H. Kottra, Rebecca Gonzalez, Jennifer M. Logue, Farhad Khimani, Hany Elmariah, Michael D. Jain, Taiga Nishihori, Hien D. Liu, Jason Brayer, Ken H. Shain, Rachid Baz, Frederick L. Locke, Melissa Alsina, Marco L. Davila
Journal: Blood
Blood (2022) 140 (Supplement 1): 12778–12780.
https://doi.org/10.1182/blood-2022-158080
Published: 2022
Journal Articles

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Hassaan Yasin, Mahrukh Naqvi, Jongphil Kim, Rawan Faramand, Omar Alexis Castaneda Puglianini, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Michael Nieder, Joseph Pidala, Nelli Bejanyan
Journal: Blood
Blood (2022) 140 (Supplement 1): 4886–4888.
https://doi.org/10.1182/blood-2022-170696
Published: 2022
Journal Articles

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Taiga Nishihori, Ciara L. Freeman, Doris K. Hansen, Brandon J. Blue, Omar Alexis Castaneda Puglianini, Jongphil Kim, Ariel F. Grajales-Cruz, Jason Brayer, Jose Ochoa, Hien D. Liu, Kenneth H. Shain, Rachid C. Baz, Frederick L. Locke, Melissa Alsina
Journal: Blood
Blood (2022) 140 (Supplement 1): 4856–4858.
https://doi.org/10.1182/blood-2022-168888
Published: 2022
Journal Articles

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, Doris K. Hansen, Hien D. Liu, Omar Alexis Castaneda Puglianini, Ciara L. Freeman, Brandon J. Blue, Jason Brayer, Jongphil Kim, Ariel F Grajales-Cruz, Jose Ochoa, Rachid C. Baz, Kenneth H. Shain, Frederick L. Locke, Melissa Alsina
Journal: Blood
Blood (2022) 140 (Supplement 1): 5174–5176.
https://doi.org/10.1182/blood-2022-171117
Published: 2022
Journal Articles

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B Wagner, M. Hakan Kocoglu, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Aishwarya Sannareddy, Gary Simmons, James Davis, Nilesh Kalariya, Lauren C. Peres, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina Patel, Omar Alexis Castaneda Puglianini
Journal: Blood
Blood (2022) 140 (Supplement 1): 1856–1858.
https://doi.org/10.1182/blood-2022-164884
Published: 2022
Journal Articles

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Lauren C. Peres, Laura B. Oswald, Christen Dillard, Gabriel De Avila, Taiga Nishihori, Brandon J. Blue, Ciara L. Freeman, Frederick L. Locke, Melissa Alsina, Omar Alexis Castaneda Puglianini, Leyla O. Shune, Douglas W. Sborov, Charlotte B Wagner, Danai Dima, Hamza Hashmi, James Davis, M. Hakan Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher J. Ferreri, Aishwarya Sannareddy, Aimaz Afrough, Peter M. Voorhees, Jack Khouri, Joseph P. McGuirk, Surbhi Sidana, Doris K. Hansen, Krina Patel
Journal: Blood
Blood (2022) 140 (Supplement 1): 623–625.
https://doi.org/10.1182/blood-2022-158478
Published: 2022
Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3314.
https://doi.org/10.1182/blood-2019-131321
Published: 2019
Journal Articles

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Ariel F Grajales-Cruz, MD, Cristian Ivan Rodriguez Arocho, MD, Ashley Rose, MD, Jamie Shapiro, PharmD, Elizabeth Finley-Oliver, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Taiga Nishihori, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Melissa Alsina, MD, Rachid Baz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3183.
https://doi.org/10.1182/blood-2019-129021
Published: 2019
Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3189.
https://doi.org/10.1182/blood-2019-131451
Published: 2019